首页 > 最新文献

World Journal of Surgical Oncology最新文献

英文 中文
Efficacy and toxicity of KRASG12C inhibitors in advanced solid tumors: a meta-analysis. KRASG12C 抑制剂在晚期实体瘤中的疗效和毒性:一项荟萃分析。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-07-16 DOI: 10.1186/s12957-024-03449-8
Shoutao Dang, Shuyang Zhang, Jingyang Zhao, Wei Li

Background: The efficacy and toxicity of KRASG12C inhibitors were evaluated for advanced solid tumors in several studies; however, the results were not fully consistent.

Methods: Clinical trials evaluating KRASG12C inhibitors for advanced solid tumors were searched from PubMed, Embase, and Cochrane Library online databases up to 31st December 2023. The characteristics of the studies and the results of objective response rate (ORR), disease control rate (DCR), duration of response (DoR), progression-free survival (PFS) rate, overall survival (OS) rate, and treatment-related adverse events (trAEs) were extracted.

Results: Ten studies with 925 heavily pretreated advanced patients harboring KRASG12C mutation were included. For total population, the pooled analysis of ORR was 28.6% (95%CI, 21.2-36.6%), DCR was 85.5% (95%CI, 82.2-88.6%), PFS rate at 6 months (PFS6) was 49.6% (95%CI, 41.4-57.9%), PFS rate at 12 months (PFS12) was 26.7% (95%CI, 19.8-34.1%), OS rates at 6 months (OS6) was 76.2% (95%CI, 68.8-82.9%), OS rates at 12 months (OS12) was 47.8% (95%CI, 38.6-57.0%). The pooled analysis of any grade trAEs was 79.3% (95%CI, 66.2-90.0%) and grade three or more trAEs was 24.4% (95%CI, 16.7-32.9%). The median time to response and DoR results from individual data were 1.39 months (95%CI, 1.37-1.41 months) and 10.54 months (95%CI, 7.72-13.36 months). Sotorasib had significantly lower pooled incidences of any trAEs (OR, 0.07, 95%CI, 0.03-0.14) and grade three or more trAES (OR, 0.34, 95%CI, 0.24-0.49) compared with adagrasib.

Conclusions: KRASG12C inhibitors have good ORR, DCR, PFS rate, OS rate, tolerable trAEs, and early response with long duration in advanced solid tumors; however, most of the pooled results were heterogeneous. Sotorasib has shown better safety results.

背景多项研究评估了KRASG12C抑制剂治疗晚期实体瘤的疗效和毒性,但结果并不完全一致:截至 2023 年 12 月 31 日,在 PubMed、Embase 和 Cochrane Library 在线数据库中检索了评估 KRASG12C 抑制剂治疗晚期实体瘤的临床试验。提取了研究的特征以及客观反应率(ORR)、疾病控制率(DCR)、反应持续时间(DoR)、无进展生存率(PFS)、总生存率(OS)和治疗相关不良事件(trAEs)的结果:结果:共纳入10项研究,925例携带KRASG12C突变的重度预处理晚期患者。总人群中,汇总分析的 ORR 为 28.6%(95%CI,21.2-36.6%),DCR 为 85.5%(95%CI,82.2-88.6%),6 个月的 PFS 率(PFS6)为 49.6%(95%CI,41.4-57.9%),12个月时的PFS率(PFS12)为26.7%(95%CI,19.8-34.1%),6个月时的OS率(OS6)为76.2%(95%CI,68.8-82.9%),12个月时的OS率(OS12)为47.8%(95%CI,38.6-57.0%)。任何等级trAEs的汇总分析结果为79.3%(95%CI,66.2-90.0%),三级或三级以上trAEs的汇总分析结果为24.4%(95%CI,16.7-32.9%)。个别数据的中位应答时间和DoR结果分别为1.39个月(95%CI,1.37-1.41个月)和10.54个月(95%CI,7.72-13.36个月)。与阿达拉昔布相比,索托拉昔布的任何trAEs(OR,0.07,95%CI,0.03-0.14)和三级或三级以上trAES(OR,0.34,95%CI,0.24-0.49)的汇总发生率明显降低:KRASG12C抑制剂在晚期实体瘤中具有良好的ORR、DCR、PFS率、OS率、可耐受的trAEs和持续时间长的早期反应;然而,大多数汇总结果是异质性的。索托拉西布的安全性较好。
{"title":"Efficacy and toxicity of KRAS<sup>G12C</sup> inhibitors in advanced solid tumors: a meta-analysis.","authors":"Shoutao Dang, Shuyang Zhang, Jingyang Zhao, Wei Li","doi":"10.1186/s12957-024-03449-8","DOIUrl":"10.1186/s12957-024-03449-8","url":null,"abstract":"<p><strong>Background: </strong>The efficacy and toxicity of KRAS<sup>G12C</sup> inhibitors were evaluated for advanced solid tumors in several studies; however, the results were not fully consistent.</p><p><strong>Methods: </strong>Clinical trials evaluating KRAS<sup>G12C</sup> inhibitors for advanced solid tumors were searched from PubMed, Embase, and Cochrane Library online databases up to 31st December 2023. The characteristics of the studies and the results of objective response rate (ORR), disease control rate (DCR), duration of response (DoR), progression-free survival (PFS) rate, overall survival (OS) rate, and treatment-related adverse events (trAEs) were extracted.</p><p><strong>Results: </strong>Ten studies with 925 heavily pretreated advanced patients harboring KRAS<sup>G12C</sup> mutation were included. For total population, the pooled analysis of ORR was 28.6% (95%CI, 21.2-36.6%), DCR was 85.5% (95%CI, 82.2-88.6%), PFS rate at 6 months (PFS6) was 49.6% (95%CI, 41.4-57.9%), PFS rate at 12 months (PFS12) was 26.7% (95%CI, 19.8-34.1%), OS rates at 6 months (OS6) was 76.2% (95%CI, 68.8-82.9%), OS rates at 12 months (OS12) was 47.8% (95%CI, 38.6-57.0%). The pooled analysis of any grade trAEs was 79.3% (95%CI, 66.2-90.0%) and grade three or more trAEs was 24.4% (95%CI, 16.7-32.9%). The median time to response and DoR results from individual data were 1.39 months (95%CI, 1.37-1.41 months) and 10.54 months (95%CI, 7.72-13.36 months). Sotorasib had significantly lower pooled incidences of any trAEs (OR, 0.07, 95%CI, 0.03-0.14) and grade three or more trAES (OR, 0.34, 95%CI, 0.24-0.49) compared with adagrasib.</p><p><strong>Conclusions: </strong>KRAS<sup>G12C</sup> inhibitors have good ORR, DCR, PFS rate, OS rate, tolerable trAEs, and early response with long duration in advanced solid tumors; however, most of the pooled results were heterogeneous. Sotorasib has shown better safety results.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141621076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A study predicting long-term survival capacity in postoperative advanced gastric cancer patients based on MAOA and subcutaneous muscle fat characteristics. 基于 MAOA 和皮下肌肉脂肪特征预测晚期胃癌术后患者长期生存能力的研究。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-07-16 DOI: 10.1186/s12957-024-03466-7
Yubo Han, Yaoyuan Chang, Jiaqi Wang, Nanbo Li, Yang Yu, Zhengbo Yang, Weipeng Lv, Wenfei Liu, Jiajun Yin, Ju Wu

Background: The prognosis of advanced gastric cancer (AGC) is relatively poor, and long-term survival depends on timely intervention. Currently, predicting survival rates remains a hot topic. The application of radiomics and immunohistochemistry-related techniques in cancer research is increasingly widespread. However, their integration for predicting long-term survival in AGC patients has not been fully explored.

Methods: We Collected 150 patients diagnosed with AGC at the Affiliated Zhongshan Hospital of Dalian University who underwent radical surgery between 2015 and 2019. Following strict inclusion and exclusion criteria, 90 patients were included in the analysis. We Collected postoperative pathological specimens from enrolled patients, analyzed the expression levels of MAOA using immunohistochemical techniques, and quantified these levels as the MAOAHScore. Obtained plain abdominal CT images from patients, delineated the region of interest at the L3 vertebral body level, and extracted radiomics features. Lasso Cox regression was used to select significant features to establish a radionics risk score, convert it into a categorical variable named risk, and use Cox regression to identify independent predictive factors for constructing a clinical prediction model. ROC, DCA, and calibration curves validated the model's performance.

Results: The enrolled patients had an average age of 65.71 years, including 70 males and 20 females. Multivariate Cox regression analysis revealed that risk (P = 0.001, HR = 3.303), MAOAHScore (P = 0.043, HR = 2.055), and TNM stage (P = 0.047, HR = 2.273) emerged as independent prognostic risk factors for 3-year overall survival (OS) and The Similar results were found in the analysis of 3-year disease-specific survival (DSS). The nomogram developed could predict 3-year OS and DSS rates, with areas under the ROC curve (AUCs) of 0.81 and 0.797, respectively. Joint calibration and decision curve analyses (DCA) confirmed the nomogram's good predictive performance and clinical utility.

Conclusion: Integrating immunohistochemistry and muscle fat features provides a more accurate prediction of long-term survival in gastric cancer patients. This study offers new perspectives and methods for a deeper understanding of survival prediction in AGC.

背景:晚期胃癌(AGC)的预后相对较差,长期生存取决于及时干预。目前,预测生存率仍是一个热门话题。放射组学和免疫组化相关技术在癌症研究中的应用越来越广泛。然而,它们在预测 AGC 患者长期生存率方面的整合尚未得到充分探索:我们收集了大连大学附属中山医院在2015年至2019年期间确诊的150例接受根治术的AGC患者。按照严格的纳入和排除标准,90 例患者纳入分析。我们收集了入选患者的术后病理标本,利用免疫组化技术分析了MAOA的表达水平,并将其量化为MAOAHScore。获取患者的腹部 CT 平片,在 L3 椎体水平划定感兴趣区,并提取放射组学特征。利用 Lasso Cox 回归选择重要特征,建立放射组学风险评分,将其转换为名为风险的分类变量,并利用 Cox 回归确定独立预测因素,以构建临床预测模型。ROC、DCA和校准曲线验证了模型的性能:入组患者的平均年龄为 65.71 岁,其中男性 70 人,女性 20 人。多变量 Cox 回归分析显示,风险(P = 0.001,HR = 3.303)、MAOAHScore(P = 0.043,HR = 2.055)和 TNM 分期(P = 0.047,HR = 2.273)成为 3 年总生存期(OS)和 3 年疾病特异性生存期(DSS)的独立预后风险因素。开发的提名图可以预测 3 年 OS 和 DSS 率,其 ROC 曲线下面积(AUC)分别为 0.81 和 0.797。联合校准和决策曲线分析(DCA)证实了该提名图具有良好的预测性能和临床实用性:结论:将免疫组化和肌肉脂肪特征相结合,可以更准确地预测胃癌患者的长期生存率。这项研究为深入了解 AGC 的生存预测提供了新的视角和方法。
{"title":"A study predicting long-term survival capacity in postoperative advanced gastric cancer patients based on MAOA and subcutaneous muscle fat characteristics.","authors":"Yubo Han, Yaoyuan Chang, Jiaqi Wang, Nanbo Li, Yang Yu, Zhengbo Yang, Weipeng Lv, Wenfei Liu, Jiajun Yin, Ju Wu","doi":"10.1186/s12957-024-03466-7","DOIUrl":"10.1186/s12957-024-03466-7","url":null,"abstract":"<p><strong>Background: </strong>The prognosis of advanced gastric cancer (AGC) is relatively poor, and long-term survival depends on timely intervention. Currently, predicting survival rates remains a hot topic. The application of radiomics and immunohistochemistry-related techniques in cancer research is increasingly widespread. However, their integration for predicting long-term survival in AGC patients has not been fully explored.</p><p><strong>Methods: </strong>We Collected 150 patients diagnosed with AGC at the Affiliated Zhongshan Hospital of Dalian University who underwent radical surgery between 2015 and 2019. Following strict inclusion and exclusion criteria, 90 patients were included in the analysis. We Collected postoperative pathological specimens from enrolled patients, analyzed the expression levels of MAOA using immunohistochemical techniques, and quantified these levels as the MAOAHScore. Obtained plain abdominal CT images from patients, delineated the region of interest at the L3 vertebral body level, and extracted radiomics features. Lasso Cox regression was used to select significant features to establish a radionics risk score, convert it into a categorical variable named risk, and use Cox regression to identify independent predictive factors for constructing a clinical prediction model. ROC, DCA, and calibration curves validated the model's performance.</p><p><strong>Results: </strong>The enrolled patients had an average age of 65.71 years, including 70 males and 20 females. Multivariate Cox regression analysis revealed that risk (P = 0.001, HR = 3.303), MAOAHScore (P = 0.043, HR = 2.055), and TNM stage (P = 0.047, HR = 2.273) emerged as independent prognostic risk factors for 3-year overall survival (OS) and The Similar results were found in the analysis of 3-year disease-specific survival (DSS). The nomogram developed could predict 3-year OS and DSS rates, with areas under the ROC curve (AUCs) of 0.81 and 0.797, respectively. Joint calibration and decision curve analyses (DCA) confirmed the nomogram's good predictive performance and clinical utility.</p><p><strong>Conclusion: </strong>Integrating immunohistochemistry and muscle fat features provides a more accurate prediction of long-term survival in gastric cancer patients. This study offers new perspectives and methods for a deeper understanding of survival prediction in AGC.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141621074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chemoradiotherapy versus radiotherapy in high risk salivary gland cancer 高风险唾液腺癌的化疗与放疗对比
IF 3.2 3区 医学 Q3 ONCOLOGY Pub Date : 2024-07-11 DOI: 10.1186/s12957-024-03456-9
Yicheng Shen, Jiebo Shan
The aim of this study was to investigate the potential survival benefits associated with chemoradiotherapy (CRT) as opposed to radiotherapy (RT) in patients with resected high-risk salivary gland cancer (SGC), with a specific focus on determining whether these benefits are influenced by the number of high-risk variables. Patients who underwent surgical treatment for high-risk SGC were retrospectively enrolled and categorized into either CRT or RT groups. The impact of adjuvant therapy on locoregional control (LRC) and overall survival (OS) was assessed using a multivariable Cox model. A total of 152 patients were included following propensity score-matching. In comparison to RT, CRT did not demonstrate a significant survival advantage in terms of LRC (p = 0.485, HR: 1.14, 95%CI: 0.36–4.22) and OS (p = 0.367, HR: 0.99, 95%CI: 0.17–3.87) in entire population. But among patients with T3/4 stage, high-grade tumors, and 5 or more positive lymph nodes, the addition of chemotherapy to RT significantly (p = 0.042) correlated with a 15% reduction in the risk of cancer recurrence (95%CI: 4-54%). Conversely, in other subgroups with varying combinations of high-risk variables, CRT did not provide additional survival benefits for LRC and OS compared to RT. Adjuvant chemotherapy may be considered in conjunction with RT specifically in cases where there is a presence of T3/4 stage, high-grade tumors, and 5 or more metastatic lymph nodes in high-risk SGC.
本研究旨在探讨化疗(CRT)相对于放疗(RT)对切除的高危唾液腺癌(SGC)患者的潜在生存益处,重点是确定这些益处是否受高危变量数量的影响。对接受手术治疗的高危SGC患者进行了回顾性登记,并将其分为CRT组或RT组。采用多变量Cox模型评估了辅助治疗对局部区域控制(LRC)和总生存率(OS)的影响。经过倾向评分匹配后,共纳入了152名患者。与 RT 相比,CRT 在整个人群中的 LRC(p = 0.485,HR:1.14,95%CI:0.36-4.22)和 OS(p = 0.367,HR:0.99,95%CI:0.17-3.87)生存率方面并无明显优势。但在T3/4期、高级别肿瘤和5个或5个以上淋巴结阳性的患者中,在RT基础上加用化疗与癌症复发风险降低15%(95%CI:4%-54%)显著相关(p = 0.042)。相反,在具有不同高危变量组合的其他亚组中,与 RT 相比,CRT 并未为 LRC 和 OS 带来额外的生存益处。特别是在高危SGC存在T3/4期、高级别肿瘤和5个或更多转移淋巴结的情况下,可以考虑在RT的同时进行辅助化疗。
{"title":"Chemoradiotherapy versus radiotherapy in high risk salivary gland cancer","authors":"Yicheng Shen, Jiebo Shan","doi":"10.1186/s12957-024-03456-9","DOIUrl":"https://doi.org/10.1186/s12957-024-03456-9","url":null,"abstract":"The aim of this study was to investigate the potential survival benefits associated with chemoradiotherapy (CRT) as opposed to radiotherapy (RT) in patients with resected high-risk salivary gland cancer (SGC), with a specific focus on determining whether these benefits are influenced by the number of high-risk variables. Patients who underwent surgical treatment for high-risk SGC were retrospectively enrolled and categorized into either CRT or RT groups. The impact of adjuvant therapy on locoregional control (LRC) and overall survival (OS) was assessed using a multivariable Cox model. A total of 152 patients were included following propensity score-matching. In comparison to RT, CRT did not demonstrate a significant survival advantage in terms of LRC (p = 0.485, HR: 1.14, 95%CI: 0.36–4.22) and OS (p = 0.367, HR: 0.99, 95%CI: 0.17–3.87) in entire population. But among patients with T3/4 stage, high-grade tumors, and 5 or more positive lymph nodes, the addition of chemotherapy to RT significantly (p = 0.042) correlated with a 15% reduction in the risk of cancer recurrence (95%CI: 4-54%). Conversely, in other subgroups with varying combinations of high-risk variables, CRT did not provide additional survival benefits for LRC and OS compared to RT. Adjuvant chemotherapy may be considered in conjunction with RT specifically in cases where there is a presence of T3/4 stage, high-grade tumors, and 5 or more metastatic lymph nodes in high-risk SGC.","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141586767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short-term OS as a surrogate endpoint for 5-year OS in nasopharyngeal carcinoma in non-endemic area. 将短期生存期作为非流行区鼻咽癌 5 年生存期的替代终点。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-07-11 DOI: 10.1186/s12957-024-03460-z
Ying Guan, Lu Han, Han-Yin Luo, Bin-Bin Yu, Shi-Ting Huang

Purpose: To address this evidence gap and validate short-term OS at less than 5 years as a reliable surrogate endpoint for 5-year OS.

Methods: We analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database, focusing on non-metastatic NPC patients diagnosed between 2010 and 2015. Patients were categorized into radiotherapy and chemoradiotherapy groups.

Results: This retrospective study examined 2,047 non-metastatic NPC patients. Among them, 217 received radiotherapy, and 1,830 received chemoradiotherapy. Our analysis results indicated that the 4-year OS may serve as a reliable surrogate endpoint for patients with AJCC clinical stage I (80 vs. 78%, P = 0.250), regardless of the treatment received. Specifically, in the radiotherapy group, patients with stage I, T0-T1, and N0 NPC showed similar OS rates at 4 and 5 years (83 vs. 82%, P = 1.000; 78 vs. 76%, P = 0.250; 78 vs. 77%, P = 0.500, respectively). Similarly, patients with stage II-IV, T2-T4, and N1-3 NPC showed no significant difference in OS rates between 3 and 5 years (57 vs. 51%, P = 0.063; 52 vs. 46%, P = 0.250; 54 vs. 46%, P = 0.125, respectively) in the radiotherapy group. In the chemoradiotherapy group, only the 3-year OS rate did not significantly differ from that at 5 years in stage I patients (79vs. 72%, P = 0.063).

Conclusions: Our study suggests that short-term surrogate endpoints may be valuable for evaluating 5-year OS outcomes in NPC patients in non-endemic areas.

目的:填补这一证据空白,并验证小于5年的短期OS是5年OS的可靠替代终点:我们分析了来自监测、流行病学和最终结果(SEER)数据库的数据,重点关注2010年至2015年间确诊的非转移性鼻咽癌患者。患者被分为放疗组和化放疗组:这项回顾性研究共调查了2047名非转移性鼻咽癌患者。其中217人接受了放疗,1830人接受了化放疗。我们的分析结果表明,对于AJCC临床分期为I期的患者,无论接受何种治疗,4年生存率都可以作为可靠的替代终点(80%对78%,P=0.250)。具体而言,在放疗组中,I期、T0-T1和N0 NPC患者的4年和5年OS率相似(分别为83 vs. 82%,P = 1.000;78 vs. 76%,P = 0.250;78 vs. 77%,P = 0.500)。同样,在放疗组中,II-IV期、T2-T4期和N1-3期鼻咽癌患者的3年和5年的OS率没有明显差异(分别为57 vs. 51%,P = 0.063;52 vs. 46%,P = 0.250;54 vs. 46%,P = 0.125)。在化疗放疗组中,只有I期患者的3年OS率与5年OS率没有显著差异(79vs.72%,P=0.063):我们的研究表明,短期替代终点可能对评估非流行地区鼻咽癌患者的 5 年 OS 结果有价值。
{"title":"Short-term OS as a surrogate endpoint for 5-year OS in nasopharyngeal carcinoma in non-endemic area.","authors":"Ying Guan, Lu Han, Han-Yin Luo, Bin-Bin Yu, Shi-Ting Huang","doi":"10.1186/s12957-024-03460-z","DOIUrl":"10.1186/s12957-024-03460-z","url":null,"abstract":"<p><strong>Purpose: </strong>To address this evidence gap and validate short-term OS at less than 5 years as a reliable surrogate endpoint for 5-year OS.</p><p><strong>Methods: </strong>We analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database, focusing on non-metastatic NPC patients diagnosed between 2010 and 2015. Patients were categorized into radiotherapy and chemoradiotherapy groups.</p><p><strong>Results: </strong>This retrospective study examined 2,047 non-metastatic NPC patients. Among them, 217 received radiotherapy, and 1,830 received chemoradiotherapy. Our analysis results indicated that the 4-year OS may serve as a reliable surrogate endpoint for patients with AJCC clinical stage I (80 vs. 78%, P = 0.250), regardless of the treatment received. Specifically, in the radiotherapy group, patients with stage I, T0-T1, and N0 NPC showed similar OS rates at 4 and 5 years (83 vs. 82%, P = 1.000; 78 vs. 76%, P = 0.250; 78 vs. 77%, P = 0.500, respectively). Similarly, patients with stage II-IV, T2-T4, and N1-3 NPC showed no significant difference in OS rates between 3 and 5 years (57 vs. 51%, P = 0.063; 52 vs. 46%, P = 0.250; 54 vs. 46%, P = 0.125, respectively) in the radiotherapy group. In the chemoradiotherapy group, only the 3-year OS rate did not significantly differ from that at 5 years in stage I patients (79vs. 72%, P = 0.063).</p><p><strong>Conclusions: </strong>Our study suggests that short-term surrogate endpoints may be valuable for evaluating 5-year OS outcomes in NPC patients in non-endemic areas.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11238357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141580989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Malignant solitary fibrous tumor of the kidney with IGF2 secretion and without hypoglycemia. 肾脏恶性单发纤维瘤伴有 IGF2 分泌,但无低血糖症。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-07-09 DOI: 10.1186/s12957-024-03342-4
Luting Zhou, Yang Liu, Teng Xu, Lei Dong, Xiaoqun Yang, Chaofu Wang

Background: Solitary fibrous tumor (SFT) is a rare fibroblastic mesenchymal tumor that mostly involves the pleura and infrequently involves extra-pleural sites. De novo SFT of the kidney is uncommon, and malignant SFT is extremely rare.

Case presentation: We report a case of a 51-year-old man with a large malignant SFT in the left kidney. Pathological examination confirmed the diagnosis of SFT based on typical morphology, nuclear STAT6 expression, and NAB2-STAT6 gene fusion. The malignant subtype was determined by a large tumor size (≥ 15 cm) and high mitotic counts (8/10 high-power fields). KRAS mutation was identified by DNA sequencing. Insulin-like growth factor 2 (IGF2) was diffusely and strongly expressed in tumor cells, however, hypoglycemia was not observed. Hyperglycemia and high adrenocorticotropic hormone (ACTH) concentration were observed one month after surgery. Hormone measurements revealed normal blood cortisol and aldosterone levels, and increased urinary free cortisol level. A pituitary microadenoma was identified using brain magnetic resonance imaging, which may be responsible for the promotion of hyperglycemia.

Conclusions: We report a case of renal malignant SFT with a KRAS mutation, which was previously unreported in SFT and may be associated with its malignant behavior. Additionally, we emphasize that malignant SFT commonly causes severe hypoglycemia due to the production of IGF2. However, this effect may be masked by the presence of other lesions that promote hyperglycemia. Therefore, when encountering a malignant SFT with diffuse and strong IGF2 expression and without hypoglycemia, other lesions promoting hyperglycemia need to be ruled out.

背景:孤立性纤维瘤(SFT)是一种罕见的纤维母细胞间充质肿瘤,大多累及胸膜,很少累及胸膜外部位。肾脏新发的 SFT 并不常见,恶性 SFT 则极为罕见:我们报告了一例 51 岁男性左肾巨大恶性 SFT 病例。病理检查根据典型形态、核 STAT6 表达和 NAB2-STAT6 基因融合确诊为 SFT。肿瘤体积大(≥ 15 厘米)、有丝分裂计数高(8/10 个高倍视野)可确定为恶性亚型。通过DNA测序确定了KRAS突变。胰岛素样生长因子2(IGF2)在肿瘤细胞中呈弥漫性强表达,但未观察到低血糖。术后一个月观察到高血糖和高促肾上腺皮质激素(ACTH)浓度。激素测定显示血液皮质醇和醛固酮水平正常,尿游离皮质醇水平升高。脑磁共振成像发现了垂体微腺瘤,这可能是导致高血糖的原因:我们报告了一例伴有 KRAS 基因突变的肾脏恶性 SFT 病例,该基因突变以前从未在 SFT 中报道过,可能与 SFT 的恶性行为有关。此外,我们还强调,恶性 SFT 通常会因 IGF2 的产生而导致严重低血糖。然而,这种影响可能会被其他促进高血糖的病变所掩盖。因此,当遇到弥漫性强 IGF2 表达且无低血糖的恶性 SFT 时,需要排除其他促进高血糖的病变。
{"title":"Malignant solitary fibrous tumor of the kidney with IGF2 secretion and without hypoglycemia.","authors":"Luting Zhou, Yang Liu, Teng Xu, Lei Dong, Xiaoqun Yang, Chaofu Wang","doi":"10.1186/s12957-024-03342-4","DOIUrl":"10.1186/s12957-024-03342-4","url":null,"abstract":"<p><strong>Background: </strong>Solitary fibrous tumor (SFT) is a rare fibroblastic mesenchymal tumor that mostly involves the pleura and infrequently involves extra-pleural sites. De novo SFT of the kidney is uncommon, and malignant SFT is extremely rare.</p><p><strong>Case presentation: </strong>We report a case of a 51-year-old man with a large malignant SFT in the left kidney. Pathological examination confirmed the diagnosis of SFT based on typical morphology, nuclear STAT6 expression, and NAB2-STAT6 gene fusion. The malignant subtype was determined by a large tumor size (≥ 15 cm) and high mitotic counts (8/10 high-power fields). KRAS mutation was identified by DNA sequencing. Insulin-like growth factor 2 (IGF2) was diffusely and strongly expressed in tumor cells, however, hypoglycemia was not observed. Hyperglycemia and high adrenocorticotropic hormone (ACTH) concentration were observed one month after surgery. Hormone measurements revealed normal blood cortisol and aldosterone levels, and increased urinary free cortisol level. A pituitary microadenoma was identified using brain magnetic resonance imaging, which may be responsible for the promotion of hyperglycemia.</p><p><strong>Conclusions: </strong>We report a case of renal malignant SFT with a KRAS mutation, which was previously unreported in SFT and may be associated with its malignant behavior. Additionally, we emphasize that malignant SFT commonly causes severe hypoglycemia due to the production of IGF2. However, this effect may be masked by the presence of other lesions that promote hyperglycemia. Therefore, when encountering a malignant SFT with diffuse and strong IGF2 expression and without hypoglycemia, other lesions promoting hyperglycemia need to be ruled out.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11234528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141564540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted axillary dissection reduces residual nodal disease in clinically node- positive breast cancer after neoadjuvant chemotherapy. 靶向腋窝切除术可减少新辅助化疗后临床结节阳性乳腺癌的残余结节病。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-07-06 DOI: 10.1186/s12957-024-03413-6
Neslihan Cabıoğlu, Hasan Karanlık, Ravza Yılmaz, Selman Emiroğlu, Mustafa Tükenmez, Süleyman Bademler, Duygu Has Şimşek, Tarık Recep Kantarcı, İnci Kızıldağ Yirgin, Aysel Bayram, Memduh Dursun

Background: Any advantage of performing targeted axillary dissection (TAD) compared to sentinel lymph node (SLN) biopsy (SLNB) is under debate in clinically node-positive (cN+) patients diagnosed with breast cancer. Our objective was to assess the feasibility of the removal of the clipped node (RCN) with TAD or without imaging-guided localisation by SLNB to reduce the residual axillary disease in completion axillary lymph node dissection (cALND) in cN+ breast cancer.

Methods: A combined analysis of two prospective cohorts, including 253 patients who underwent SLNB with/without TAD and with/without ALND following NAC, was performed. Finally, 222 patients (cT1-3N1/ycN0M0) with a clipped lymph node that was radiologically visible were analyzed.

Results: Overall, the clipped node was successfully identified in 246 patients (97.2%) by imaging. Of 222 patients, the clipped lymph nodes were non-SLNs in 44 patients (19.8%). Of patients in cohort B (n=129) with TAD, the clipped node was successfully removed by preoperative image-guided localisation, or the clipped lymph node was removed as the SLN as detected on preoperative SPECT-CT. Among patients with ypSLN(+) (n=109), no significant difference was found in non-SLN positivity at cALND between patients with TAD and RCN (41.7% vs. 46.9%, p=0.581). In the subgroup with TAD with axillary lymph node dissection (ALND; n=60), however, patients with a lymph node (LN) ratio (LNR) less than 50% and one metastatic LN in the TAD specimen were found to have significantly decreased non-SLN positivity compared to others (27.6% vs. 54.8%, p=0.032, and 22.2% vs. 50%, p=0.046).

Conclusions: TAD by imaging-guided localisation is feasible with excellent identification rates of the clipped node. This approach has also been found to reduce the additional non-SLN positivity rate to encourage omitting ALND in patients with a low metastatic burden undergoing TAD.

背景:在临床结节阳性(cN+)的乳腺癌患者中,与前哨淋巴结(SLN)活检(SLNB)相比,有针对性的腋窝清扫术(TAD)是否具有优势还存在争议。我们的目的是评估在对 cN+ 乳腺癌患者进行腋窝淋巴结清扫术(cALND)时,使用 TAD 或不使用 SLNB 在影像学引导下定位,切除剪切的结节(RCN)以减少残留腋窝疾病的可行性:对两个前瞻性队列进行了综合分析,其中包括 253 例在 NAC 后接受/不接受 TAD 的 SLNB 和接受/不接受 ALND 的患者。最后,分析了222例在放射学上可见剪切淋巴结的患者(cT1-3N1/ycN0M0):结果:总体而言,246 例患者(97.2%)通过影像学检查成功确定了剪切的淋巴结。在 222 例患者中,有 44 例(19.8%)患者的剪切淋巴结为非淋巴结。在队列 B(n=129)的 TAD 患者中,通过术前图像引导定位成功切除了被剪切的淋巴结,或将被剪切的淋巴结作为术前 SPECT-CT 检测到的 SLN 予以切除。在 ypSLN(+) 患者(n=109)中,TAD 和 RCN 患者在 cALND 时的非 SLN 阳性率无显著差异(41.7% 对 46.9%,p=0.581)。然而,在进行腋窝淋巴结清扫(ALND;n=60)的TAD亚组中,发现淋巴结(LNR)比值(LNR)小于50%且TAD标本中有一个转移LN的患者与其他患者相比,非淋巴结阳性率显著降低(27.6% vs. 54.8%,p=0.032;22.2% vs. 50%,p=0.046):结论:通过影像引导定位进行 TAD 是可行的,对切除结节的识别率极高。结论:在影像引导下进行 TAD 定位是可行的,其剪切结节的识别率极高,这种方法还能降低额外的非 SLN 阳性率,从而鼓励转移负荷较低的患者在接受 TAD 时放弃 ALND。
{"title":"Targeted axillary dissection reduces residual nodal disease in clinically node- positive breast cancer after neoadjuvant chemotherapy.","authors":"Neslihan Cabıoğlu, Hasan Karanlık, Ravza Yılmaz, Selman Emiroğlu, Mustafa Tükenmez, Süleyman Bademler, Duygu Has Şimşek, Tarık Recep Kantarcı, İnci Kızıldağ Yirgin, Aysel Bayram, Memduh Dursun","doi":"10.1186/s12957-024-03413-6","DOIUrl":"10.1186/s12957-024-03413-6","url":null,"abstract":"<p><strong>Background: </strong>Any advantage of performing targeted axillary dissection (TAD) compared to sentinel lymph node (SLN) biopsy (SLNB) is under debate in clinically node-positive (cN+) patients diagnosed with breast cancer. Our objective was to assess the feasibility of the removal of the clipped node (RCN) with TAD or without imaging-guided localisation by SLNB to reduce the residual axillary disease in completion axillary lymph node dissection (cALND) in cN+ breast cancer.</p><p><strong>Methods: </strong>A combined analysis of two prospective cohorts, including 253 patients who underwent SLNB with/without TAD and with/without ALND following NAC, was performed. Finally, 222 patients (cT1-3N1/ycN0M0) with a clipped lymph node that was radiologically visible were analyzed.</p><p><strong>Results: </strong>Overall, the clipped node was successfully identified in 246 patients (97.2%) by imaging. Of 222 patients, the clipped lymph nodes were non-SLNs in 44 patients (19.8%). Of patients in cohort B (n=129) with TAD, the clipped node was successfully removed by preoperative image-guided localisation, or the clipped lymph node was removed as the SLN as detected on preoperative SPECT-CT. Among patients with ypSLN(+) (n=109), no significant difference was found in non-SLN positivity at cALND between patients with TAD and RCN (41.7% vs. 46.9%, p=0.581). In the subgroup with TAD with axillary lymph node dissection (ALND; n=60), however, patients with a lymph node (LN) ratio (LNR) less than 50% and one metastatic LN in the TAD specimen were found to have significantly decreased non-SLN positivity compared to others (27.6% vs. 54.8%, p=0.032, and 22.2% vs. 50%, p=0.046).</p><p><strong>Conclusions: </strong>TAD by imaging-guided localisation is feasible with excellent identification rates of the clipped node. This approach has also been found to reduce the additional non-SLN positivity rate to encourage omitting ALND in patients with a low metastatic burden undergoing TAD.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141545351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Population-Specific gene expression profiles in prostate cancer: insights from Weighted Gene Co-expression Network Analysis (WGCNA). 前列腺癌人群特异性基因表达谱:加权基因共表达网络分析(WGCNA)的启示
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-07-05 DOI: 10.1186/s12957-024-03459-6
Laleh Manouchehri, Zahra Zinati, Leyla Nazari

This study investigates the genetic factors contributing to the disparity in prostate cancer incidence and progression among African American men (AAM) compared to European American men (EAM). The research focuses on employing Weighted Gene Co-expression Network Analysis (WGCNA) on public microarray data obtained from prostate cancer patients. The study employed WGCNA to identify clusters of genes with correlated expression patterns, which were then analyzed for their connection to population backgrounds. Additionally, pathway enrichment analysis was conducted to understand the significance of the identified gene modules in prostate cancer pathways. The Least Absolute Shrinkage and Selection Operator (LASSO) and Correlation-based Feature Selection (CFS) methods were utilized for selection of biomarker genes. The results revealed 353 differentially expressed genes (DEGs) between AAM and EAM. Six significant gene expression modules were identified through WGCNA, showing varying degrees of correlation with prostate cancer. LASSO and CFS methods pinpointed critical genes, as well as six common genes between both approaches, which are indicative of their vital role in the disease. The XGBoost classifier validated these findings, achieving satisfactory prediction accuracy. Genes such as APRT, CCL2, BEX2, MGC26963, and PLAU were identified as key genes significantly associated with cancer progression. In conclusion, the research underlines the importance of incorporating AAM and EAM population diversity in genomic studies, particularly in cancer research. In addition, the study highlights the effectiveness of integrating machine learning techniques with gene expression analysis as a robust methodology for identifying critical genes in cancer research.

本研究调查了造成非裔美国男性(AAM)与欧裔美国男性(EAM)前列腺癌发病率和进展差异的遗传因素。研究重点是在前列腺癌患者的公开微阵列数据中采用加权基因共表达网络分析(WGCNA)。该研究利用 WGCNA 找出具有相关表达模式的基因簇,然后分析这些基因与人群背景的联系。此外,研究还进行了通路富集分析,以了解所发现的基因模块在前列腺癌通路中的重要性。在选择生物标记基因时,使用了最小绝对收缩和选择操作符(LASSO)和基于相关性的特征选择(CFS)方法。结果显示,AAM 和 EAM 之间存在 353 个差异表达基因(DEGs)。通过 WGCNA 确定了六个重要的基因表达模块,它们与前列腺癌显示出不同程度的相关性。LASSO和CFS方法确定了关键基因,以及两种方法的六个共同基因,这表明它们在疾病中的重要作用。XGBoost 分类器验证了这些发现,预测准确率令人满意。APRT、CCL2、BEX2、MGC26963 和 PLAU 等基因被确定为与癌症进展密切相关的关键基因。总之,这项研究强调了将 AAM 和 EAM 群体多样性纳入基因组研究,尤其是癌症研究的重要性。此外,该研究还强调了将机器学习技术与基因表达分析相结合的有效性,这是一种在癌症研究中识别关键基因的可靠方法。
{"title":"Population-Specific gene expression profiles in prostate cancer: insights from Weighted Gene Co-expression Network Analysis (WGCNA).","authors":"Laleh Manouchehri, Zahra Zinati, Leyla Nazari","doi":"10.1186/s12957-024-03459-6","DOIUrl":"10.1186/s12957-024-03459-6","url":null,"abstract":"<p><p>This study investigates the genetic factors contributing to the disparity in prostate cancer incidence and progression among African American men (AAM) compared to European American men (EAM). The research focuses on employing Weighted Gene Co-expression Network Analysis (WGCNA) on public microarray data obtained from prostate cancer patients. The study employed WGCNA to identify clusters of genes with correlated expression patterns, which were then analyzed for their connection to population backgrounds. Additionally, pathway enrichment analysis was conducted to understand the significance of the identified gene modules in prostate cancer pathways. The Least Absolute Shrinkage and Selection Operator (LASSO) and Correlation-based Feature Selection (CFS) methods were utilized for selection of biomarker genes. The results revealed 353 differentially expressed genes (DEGs) between AAM and EAM. Six significant gene expression modules were identified through WGCNA, showing varying degrees of correlation with prostate cancer. LASSO and CFS methods pinpointed critical genes, as well as six common genes between both approaches, which are indicative of their vital role in the disease. The XGBoost classifier validated these findings, achieving satisfactory prediction accuracy. Genes such as APRT, CCL2, BEX2, MGC26963, and PLAU were identified as key genes significantly associated with cancer progression. In conclusion, the research underlines the importance of incorporating AAM and EAM population diversity in genomic studies, particularly in cancer research. In addition, the study highlights the effectiveness of integrating machine learning techniques with gene expression analysis as a robust methodology for identifying critical genes in cancer research.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11225268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141538739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management strategy for children with ovarian immature teratoma: results from a tertiary pediatric oncology center. 卵巢未成熟畸胎瘤患儿的管理策略:一家三级儿科肿瘤中心的研究结果。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-07-04 DOI: 10.1186/s12957-024-03452-z
Gehad Ahmed, Sahar Ahmed Khalil, Maged Elshafiey, Nihal Abdelfattah, Mohamed Eid, Al-Shaimaa Zakaria, Madeeha Elwakeel, Ahmed Elgendy

Objectives: We present an Egyptian study on pediatric ovarian immature teratomas (ITs), aiming to clarify our treatment strategy selection.

Methods: A retrospective review of all children with pure ovarian ITs who were treated at our institution between 2008 and 2023. The analysis included clinical characteristics, tumor staging according to Children's Oncology Group (COG), grading based on the Norris system, management, and outcomes.

Results: Thirty-two patients were included, with a median age of 9 years. All patients underwent primary surgery. Unilateral salpingo-oophorectomy was performed in 31 patients. Surgical staging was completed in all patients. Based on COG staging, there were 28 patients (87.5%) stage I, 1 (3%) stage II, and 3 (9.5%) stage III. According to Norris classification, 16 patients (50%) were classified as grade I, 9 (28%) grade II, and 7 (22%) grade III. All patients in stage I were treated using surgery-alone approach, whereas the remaining four (12.5%) received adjuvant chemotherapy. Five patients in stage I had gliomatosis peritonei (GP), and none of them underwent extensive surgery. At a median follow-up of 86 months, two patients had events. The first patient (stage III/grade I) developed IT relapse on the operative bed, and the second (stage I/grade I) had a metachronous IT on the contralateral ovary. Both patients were successfully managed with surgery followed by second-line chemotherapy. Five-year overall survival and event-free survival for all patients were 100% and 93.4%, respectively.

Conclusions: Surgery-alone strategy with close follow-up achieves excellent outcomes for localized ovarian ITs in children, irrespective of the Norris grading or the presence of GP. However, adjuvant chemotherapy is questionable for patients with incompletely resected or locally advanced tumors, and its role requires further evaluation through prospective multicentric studies with a larger sample size.

目的:我们在埃及开展了一项关于小儿卵巢未成熟畸胎瘤(ITs)的研究:我们在埃及开展了一项关于小儿卵巢未成熟畸胎瘤(ITs)的研究,旨在明确我们的治疗策略选择:方法:对2008年至2023年间在我院接受治疗的所有纯卵巢畸胎瘤患儿进行回顾性研究。分析内容包括临床特征、根据儿童肿瘤组织(COG)进行的肿瘤分期、根据诺里斯系统进行的分级、管理和结果:共纳入32名患者,中位年龄为9岁。所有患者均接受了初级手术。31名患者接受了单侧输卵管切除术。所有患者均完成了手术分期。根据COG分期,28例患者(87.5%)为I期,1例(3%)为II期,3例(9.5%)为III期。根据诺里斯分类法,16 名患者(50%)被划分为 I 期,9 名(28%)为 II 期,7 名(22%)为 III 期。所有 I 期患者都接受了单纯手术治疗,其余 4 名患者(12.5%)接受了辅助化疗。I期患者中有5人患有腹膜胶质瘤病(GP),但他们都没有接受大范围手术。在中位 86 个月的随访中,有两名患者发生了病变。第一位患者(III期/I级)在手术床上出现了IT复发,第二位患者(I期/I级)在对侧卵巢出现了IT并发症。两名患者均成功接受了手术治疗和二线化疗。所有患者的五年总生存率和无事件生存率分别为100%和93.4%:结论:无论诺里斯分级如何,也无论是否存在GP,单纯手术治疗策略加上密切随访都能为儿童卵巢局部ITs带来极佳的疗效。然而,对于肿瘤未完全切除或局部晚期的患者,辅助化疗还存在疑问,其作用需要通过样本量更大的前瞻性多中心研究来进一步评估。
{"title":"Management strategy for children with ovarian immature teratoma: results from a tertiary pediatric oncology center.","authors":"Gehad Ahmed, Sahar Ahmed Khalil, Maged Elshafiey, Nihal Abdelfattah, Mohamed Eid, Al-Shaimaa Zakaria, Madeeha Elwakeel, Ahmed Elgendy","doi":"10.1186/s12957-024-03452-z","DOIUrl":"10.1186/s12957-024-03452-z","url":null,"abstract":"<p><strong>Objectives: </strong>We present an Egyptian study on pediatric ovarian immature teratomas (ITs), aiming to clarify our treatment strategy selection.</p><p><strong>Methods: </strong>A retrospective review of all children with pure ovarian ITs who were treated at our institution between 2008 and 2023. The analysis included clinical characteristics, tumor staging according to Children's Oncology Group (COG), grading based on the Norris system, management, and outcomes.</p><p><strong>Results: </strong>Thirty-two patients were included, with a median age of 9 years. All patients underwent primary surgery. Unilateral salpingo-oophorectomy was performed in 31 patients. Surgical staging was completed in all patients. Based on COG staging, there were 28 patients (87.5%) stage I, 1 (3%) stage II, and 3 (9.5%) stage III. According to Norris classification, 16 patients (50%) were classified as grade I, 9 (28%) grade II, and 7 (22%) grade III. All patients in stage I were treated using surgery-alone approach, whereas the remaining four (12.5%) received adjuvant chemotherapy. Five patients in stage I had gliomatosis peritonei (GP), and none of them underwent extensive surgery. At a median follow-up of 86 months, two patients had events. The first patient (stage III/grade I) developed IT relapse on the operative bed, and the second (stage I/grade I) had a metachronous IT on the contralateral ovary. Both patients were successfully managed with surgery followed by second-line chemotherapy. Five-year overall survival and event-free survival for all patients were 100% and 93.4%, respectively.</p><p><strong>Conclusions: </strong>Surgery-alone strategy with close follow-up achieves excellent outcomes for localized ovarian ITs in children, irrespective of the Norris grading or the presence of GP. However, adjuvant chemotherapy is questionable for patients with incompletely resected or locally advanced tumors, and its role requires further evaluation through prospective multicentric studies with a larger sample size.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11223275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141535469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The survival prediction of advanced colorectal cancer received neoadjuvant therapy-a study of SEER database. 晚期结直肠癌接受新辅助治疗后的生存预测--一项 SEER 数据库研究。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-07-01 DOI: 10.1186/s12957-024-03458-7
Zhuo Han, Haicheng Yang, Qing Qiao, Tao Wu, Xianli He, Nan Wang

Purpose: The aim of study was to screen factors associated with the overall survival of colorectal cancer patients with lymph nodes metastasis who received neoadjuvant therapy and construct a nomogram model.

Methods: All enrolled subjects of the SEER database were randomly assigned to the training and testing group in a ratio of 3:2. The patients of Tangdu Hospital were seemed as validation group. Univariate cox regression analysis, lasso regression and random forest survival were used to screen variables related to the survival of advanced CRC patients received neoadjuvant therapy in the training group. Area under curves were adopted to evaluate the 1,3,5-year prediction value of the optimal model in three cohorts. Calibration curves were drawn to observe the prediction accuracy of the nomogram model. Decision curve analysis was used to assess the potential clinical value of the nomogram model.

Results: A total of 1833 subjects were enrolled in this study. After random allocation, 1055 cases of the SEER database served as the training group, 704 cases as the testing group and 74 patients from our center as the external validation group. Variables were screened by univariate cox regression used to construct a nomogram survival prediction model, including M, age, chemotherapy, CEA, perineural invasion, tumor size, LODDS, liver metastasis and radiation. The AUCs of the model for predicting 1-year OS in the training group, testing and validation group were 0.765 (0.703,0.827), 0.772 (0.697,0.847) and 0.742 (0.601,0.883), predicting 3-year OS were 0.761 (0.725,0.780), 0.742 (0.699,0.785), 0.733 (0.560,0.905) and 5-year OS were 0.742 (0.711,0.773), 0.746 (0.709,0.783), 0.838 (0.670,0.980), respectively. The calibration curves showed the difference between prediction probability of the model and the actual survival was not significant in three cohorts and the decision curve analysis revealed the practice clinical application value. And the prediction value of model was better for young CRC than older CRC patients.

Conclusion: A nomogram model including LODDS for the prognosis of advanced CRC received neoadjuvant therapy was constructed and verified based on the SEER database and single center practice. The accuracy and potential clinical application value of the model performed well, and the model had better predictive value for EOCRC than LOCRC.

目的:本研究旨在筛选与接受新辅助治疗的淋巴结转移结直肠癌患者总生存率相关的因素,并构建一个提名图模型:方法:将SEER数据库中的所有登记对象按3:2的比例随机分配到训练组和测试组。唐都医院的患者被视为验证组。采用单变量 cox 回归分析、lasso 回归和随机森林生存等方法筛选与训练组接受新辅助治疗的晚期 CRC 患者生存率相关的变量。采用曲线下面积评估三个队列中最优模型的 1、3、5 年预测值。绘制校准曲线以观察提名图模型的预测准确性。决策曲线分析用于评估提名图模型的潜在临床价值:本研究共招募了 1833 名受试者。随机分配后,1055 例 SEER 数据库病例作为训练组,704 例作为测试组,74 例来自本中心的患者作为外部验证组。通过单变量考克斯回归筛选出的变量包括:M、年龄、化疗、CEA、会厌浸润、肿瘤大小、LODDS、肝转移和放射。该模型在训练组、测试组和验证组预测 1 年 OS 的 AUC 分别为 0.765(0.703,0.827)、0.772(0.697,0.847)和 0.742(0.601,0.883),预测3年OS分别为0.761(0.725,0.780)、0.742(0.699,0.785)、0.733(0.560,0.905),预测5年OS分别为0.742(0.711,0.773)、0.746(0.709,0.783)、0.838(0.670,0.980)。校正曲线显示,三个队列的模型预测概率与实际生存率差异不显著,决策曲线分析显示了临床应用价值。结论:结论:基于 SEER 数据库和单中心实践,构建并验证了包括 LODDS 的晚期 CRC 新辅助治疗预后提名图模型。该模型的准确性和潜在的临床应用价值表现良好,而且该模型对EOCRC的预测价值优于LOCRC。
{"title":"The survival prediction of advanced colorectal cancer received neoadjuvant therapy-a study of SEER database.","authors":"Zhuo Han, Haicheng Yang, Qing Qiao, Tao Wu, Xianli He, Nan Wang","doi":"10.1186/s12957-024-03458-7","DOIUrl":"10.1186/s12957-024-03458-7","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of study was to screen factors associated with the overall survival of colorectal cancer patients with lymph nodes metastasis who received neoadjuvant therapy and construct a nomogram model.</p><p><strong>Methods: </strong>All enrolled subjects of the SEER database were randomly assigned to the training and testing group in a ratio of 3:2. The patients of Tangdu Hospital were seemed as validation group. Univariate cox regression analysis, lasso regression and random forest survival were used to screen variables related to the survival of advanced CRC patients received neoadjuvant therapy in the training group. Area under curves were adopted to evaluate the 1,3,5-year prediction value of the optimal model in three cohorts. Calibration curves were drawn to observe the prediction accuracy of the nomogram model. Decision curve analysis was used to assess the potential clinical value of the nomogram model.</p><p><strong>Results: </strong>A total of 1833 subjects were enrolled in this study. After random allocation, 1055 cases of the SEER database served as the training group, 704 cases as the testing group and 74 patients from our center as the external validation group. Variables were screened by univariate cox regression used to construct a nomogram survival prediction model, including M, age, chemotherapy, CEA, perineural invasion, tumor size, LODDS, liver metastasis and radiation. The AUCs of the model for predicting 1-year OS in the training group, testing and validation group were 0.765 (0.703,0.827), 0.772 (0.697,0.847) and 0.742 (0.601,0.883), predicting 3-year OS were 0.761 (0.725,0.780), 0.742 (0.699,0.785), 0.733 (0.560,0.905) and 5-year OS were 0.742 (0.711,0.773), 0.746 (0.709,0.783), 0.838 (0.670,0.980), respectively. The calibration curves showed the difference between prediction probability of the model and the actual survival was not significant in three cohorts and the decision curve analysis revealed the practice clinical application value. And the prediction value of model was better for young CRC than older CRC patients.</p><p><strong>Conclusion: </strong>A nomogram model including LODDS for the prognosis of advanced CRC received neoadjuvant therapy was constructed and verified based on the SEER database and single center practice. The accuracy and potential clinical application value of the model performed well, and the model had better predictive value for EOCRC than LOCRC.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11218294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Venous resection increases risk of chyle leak after total pancreatectomy for pancreatic tumors. 静脉切除会增加胰腺肿瘤全胰切除术后胰液漏的风险。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-06-28 DOI: 10.1186/s12957-024-03451-0
Tianyu Li, Chen Lin, Bangbo Zhao, Zeru Li, Yutong Zhao, Xianlin Han, Menghua Dai, Junchao Guo, Weibin Wang

Background: Existing research on chyle leak (CL) after pancreatic surgery is mostly focused on pancreaticoduodenectomy and lacks investigation on total pancreatectomy (TP). This study aimed to explore potential risk factors of CL and develop a predictive model for patients with pancreatic tumor undergoing TP.

Methods: This retrospective study enrolled 90 consecutive patients undergoing TP from January 2015 to December 2023 at Peking Union Medical College Hospital. According to the inclusion criteria, 79 patients were finally included in the following analysis. The LASSO regression and multivariate logistic regression analysis were performed to identify risk factors associated with CL and construct a predictive nomogram. Then, the ROC analysis, calibration curve, decision curve analysis (DCA), and clinical impact curve (CIC) were performed to assess its discrimination, accuracy, and efficacy. Due to the small sample size, we adopted the bootstrap resampling method with 500 repetitions for validation. Lastly, we plotted and analyzed the trend of postoperative drainage volume in CL patients.

Results: We revealed that venous resection (OR = 4.352, 95%CI 1.404-14.04, P = 0.011) was an independent risk factor for CL after TP. Prolonged operation time (OR = 1.473, 95%CI 1.015-2.237, P = 0.052) was also associated with an increased incidence of CL. We included these two factors in our prediction model. The area under the curve (AUC) was 0.752 (95%CI 0.622-0.874) after bootstrap. The calibration curve, DCA and CIC showed great accuracy and clinical benefit of our nomogram. In patients with CL, the mean drainage volume was significantly higher in venous resection group and grade B CL group.

Conclusion: Venous resection was an independent risk factor for chyle leak after TP. Patients undergoing vascular resection during TP should be alert for the occurrence of CL after surgery. We then constructed a nomogram consisted of venous resection and operation time to predict the odds of CL in patients undergoing TP.

背景:现有关于胰腺手术后胰液漏(CL)的研究大多集中于胰十二指肠切除术,缺乏对全胰切除术(TP)的调查。本研究旨在探索胰液漏的潜在风险因素,并为接受全胰切除术的胰腺肿瘤患者建立预测模型:这项回顾性研究纳入了 2015 年 1 月至 2023 年 12 月期间在北京协和医院接受全胰腺切除术的 90 例连续患者。根据纳入标准,最终有79名患者被纳入以下分析。通过 LASSO 回归和多变量逻辑回归分析,确定与 CL 相关的风险因素,并构建预测提名图。然后,进行 ROC 分析、校准曲线、决策曲线分析(DCA)和临床影响曲线(CIC),以评估其辨别力、准确性和有效性。由于样本量较小,我们采用了重复 500 次的引导重采样法进行验证。最后,我们绘制并分析了CL患者术后引流量的变化趋势:我们发现,静脉切除术(OR = 4.352,95%CI 1.404-14.04,P = 0.011)是 TP 术后 CL 的独立危险因素。手术时间延长(OR = 1.473,95%CI 1.015-2.237,P = 0.052)也与 CL 发生率增加有关。我们将这两个因素纳入了预测模型。经过引导后,曲线下面积(AUC)为 0.752(95%CI 0.622-0.874)。校准曲线、DCA 和 CIC 表明我们的提名图非常准确并具有临床疗效。在CL患者中,静脉切除组和B级CL组的平均引流量明显更高:结论:静脉切除是 TP 术后发生糜烂性渗漏的一个独立危险因素。结论:静脉切除是 TP 术后发生糜烂性渗漏的独立危险因素,在 TP 术中接受血管切除的患者应警惕术后发生糜烂性渗漏。然后,我们构建了一个由静脉切除和手术时间组成的提名图,以预测 TP 患者发生 CL 的几率。
{"title":"Venous resection increases risk of chyle leak after total pancreatectomy for pancreatic tumors.","authors":"Tianyu Li, Chen Lin, Bangbo Zhao, Zeru Li, Yutong Zhao, Xianlin Han, Menghua Dai, Junchao Guo, Weibin Wang","doi":"10.1186/s12957-024-03451-0","DOIUrl":"https://doi.org/10.1186/s12957-024-03451-0","url":null,"abstract":"<p><strong>Background: </strong>Existing research on chyle leak (CL) after pancreatic surgery is mostly focused on pancreaticoduodenectomy and lacks investigation on total pancreatectomy (TP). This study aimed to explore potential risk factors of CL and develop a predictive model for patients with pancreatic tumor undergoing TP.</p><p><strong>Methods: </strong>This retrospective study enrolled 90 consecutive patients undergoing TP from January 2015 to December 2023 at Peking Union Medical College Hospital. According to the inclusion criteria, 79 patients were finally included in the following analysis. The LASSO regression and multivariate logistic regression analysis were performed to identify risk factors associated with CL and construct a predictive nomogram. Then, the ROC analysis, calibration curve, decision curve analysis (DCA), and clinical impact curve (CIC) were performed to assess its discrimination, accuracy, and efficacy. Due to the small sample size, we adopted the bootstrap resampling method with 500 repetitions for validation. Lastly, we plotted and analyzed the trend of postoperative drainage volume in CL patients.</p><p><strong>Results: </strong>We revealed that venous resection (OR = 4.352, 95%CI 1.404-14.04, P = 0.011) was an independent risk factor for CL after TP. Prolonged operation time (OR = 1.473, 95%CI 1.015-2.237, P = 0.052) was also associated with an increased incidence of CL. We included these two factors in our prediction model. The area under the curve (AUC) was 0.752 (95%CI 0.622-0.874) after bootstrap. The calibration curve, DCA and CIC showed great accuracy and clinical benefit of our nomogram. In patients with CL, the mean drainage volume was significantly higher in venous resection group and grade B CL group.</p><p><strong>Conclusion: </strong>Venous resection was an independent risk factor for chyle leak after TP. Patients undergoing vascular resection during TP should be alert for the occurrence of CL after surgery. We then constructed a nomogram consisted of venous resection and operation time to predict the odds of CL in patients undergoing TP.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11214213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
World Journal of Surgical Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1